Traditional ADCs deliver less than 1% of the chemotherapy payload to the tumor and 99% of the payload to healthy cells. Payload delivery to healthy cells yields off-target toxicities. Super-ADCs have the potential to solve the safety concerns of ADCs by enhancing the payload delivery mechanism using an oligomerizing membrane binding peptide that improves tumor cell uptake.
Enhanced Membrane Loading
Super-ADCs incorporate multivalent antibodies that engage a sequential process to load onto cancer cells. In the first step, a tumor specific antigen tethers the antibody. In the next step, restricted diffusion drives direct interaction of the membrane binding peptide with membrane lipids. Finally, slow dissociation from the target antigen enables the Super-ADC to accumulate on the surface.
Enhanced Clustering & Internalization
Our membrane binding peptides are engineered to cluster only in the membrane environment. This context dependent self-association favors internalization through the natural endocytic pathways that are shared by all human cells.
Partner With Us
Our approach has the potential to improve the therapeutic index of existing assets, to unlock novel targets with low internalization, and to enable lower potency payloads to be effective in the ADC field. We aim to leverage Super-ADCs in co-development partnerships to impact the safety profile of ADCs and propel them toward first line therapy.
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
